Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins
about
The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionLlama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral moleculesChimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteinsHigh level expression of soluble glycoproteins in the allantoic fluid of embryonated chicken eggs using a Sendai virus minigenome systemMolecular epidemiology of respiratory syncytial virus infections among children with acute respiratory symptoms in a community over three seasons.Unusual antigenic and genetic characteristics of human respiratory syncytial viruses isolated in Cuba.Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccineRespiratory syncytial virus genetic and antigenic diversity.Respiratory syncytial virus infections in infants affected by primary immunodeficiency.Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vectorHyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.Animal pneumoviruses: molecular genetics and pathogenesis.Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseRespiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine.Molecular characterization of an outbreak of respiratory syncytial virus (subgroup A) in Havana, Cuba, by monoclonal antibodies and restriction mapping (N gene).Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?Pediatric RSV infection during two winter seasons in British Columbia: A role for subgroup analysis in young children?Novel antigens for RSV vaccines.Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigensGeneration and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.Identification of a variant subgroup A strain of respiratory syncytial virus.ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation.Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus.Vaccines against respiratory syncytial virus: The time has finally come.Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.Differentiation of respiratory syncytial virus subgroups with cDNA probes in a nucleic acid hybridization assay.Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro.Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions.Insertion of the two cleavage sites of the respiratory syncytial virus fusion protein in Sendai virus fusion protein leads to enhanced cell-cell fusion and a decreased dependency on the HN attachment protein for activity.Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.Antigenic structure of human respiratory syncytial virus fusion glycoprotein.Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein.Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein.Oligo(A) sequences of human respiratory syncytial virus G protein gene: assessment of their genetic stability in frameshift mutants.
P2860
Q26864494-BB865373-5F12-4CA5-9353-49BC8DF99BA9Q28741431-97961F66-5B07-4044-AEE4-7DCD39DB32A4Q30708312-A60E7B10-2769-4444-B1FC-991187E429D7Q33281306-C0742E02-F901-4857-AC6A-E3D96EF14FBEQ33592351-DC2075CE-7F1A-4AE3-A528-F9CBA80FE6D2Q33784034-40DAA16C-F879-4B53-9795-D0F379742920Q33793103-0A429D00-2559-43A7-8F18-F5757BB5F8ABQ33812405-B7C3D341-244A-48F7-8D3E-3A785B72BA9BQ33892605-3190179A-4928-403B-93F7-825354087D14Q33934074-62809185-D370-4CFD-9448-A0676CC658EBQ34302198-693CF67C-BF52-4A99-A53D-270F1EC1A73BQ34307704-D883667A-F744-4458-BAB8-9C43A76C0FD2Q34313560-336AE395-6D55-433D-ADB2-13976C9AA12DQ34330690-C57E6F45-C906-462C-846D-B287C3612EC8Q34464738-731B4B5F-695D-40FB-86EE-8550C2F904C8Q35231277-4B0188F6-87B6-4442-965E-9211EECA39DBQ35861139-578C1C78-44CE-479D-9D86-B09A932ABB49Q35893104-07C35F3E-549E-481F-9F9B-789CF257D919Q36005960-37AEF515-D3ED-4C7B-B67F-F90CECD432EAQ36128048-85EC7462-F7B6-4D07-BDCF-A8FEF23BA0E6Q36155501-157AFC92-CAB9-4A9B-9A9E-C0DF26B8B9D8Q36438987-4C38DD71-C2F7-4981-8C43-447A852F6AAEQ36540051-276B1970-58EB-4B96-910A-A4F4ADDE6C54Q36694038-C6740638-E011-49A1-9A79-BF9BAC247F84Q36913291-BB2FA000-2104-4DCA-A654-104D94C1D08BQ37018347-AE1C9078-D350-49D1-A664-4F9274E2EF8FQ37069783-278EFCE9-7950-4CDB-A8C7-1AD786F9C395Q37187290-35F718A2-0ACB-4BD3-AB39-D2932210E812Q37536191-516FBD6C-BB18-4355-BB9C-966FCEB76A96Q38334591-94234AD0-4EB8-4180-AC88-C6EE02699ACEQ38362415-A981FAD0-F816-4640-9FC3-494815027BAAQ38609801-DF7DDC39-889C-48D5-BD4F-0A1A04FED93DQ38637248-F93350FD-14A2-4573-B037-5D4ABE82A2A3Q38750689-82F2C58D-3FA2-49FD-8604-8900CD4A7DB3Q39289416-3E0024DA-B9B7-4671-9327-CE17D446A275Q39579940-F56DF832-FC19-430C-BE03-C313FF7B3AF1Q39695161-C07BB902-D599-40FB-BD8C-D8C5FF5679DDQ39869992-EE64267B-29D2-4AF5-AE0E-4494C984BF03Q40041314-B6CEC09D-3969-4F3E-AA73-FABBB411E6C5Q40041322-3F648922-65D4-480C-A70F-42B92016AED7
P2860
Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Marked differences in the anti ...... al virus F and G glycoproteins
@ast
Marked differences in the anti ...... al virus F and G glycoproteins
@en
type
label
Marked differences in the anti ...... al virus F and G glycoproteins
@ast
Marked differences in the anti ...... al virus F and G glycoproteins
@en
prefLabel
Marked differences in the anti ...... al virus F and G glycoproteins
@ast
Marked differences in the anti ...... al virus F and G glycoproteins
@en
P2093
P2860
P1433
P1476
Marked differences in the anti ...... al virus F and G glycoproteins
@en
P2093
García-Barreno B
Perez-Breña P
P2860
P304
P407
P577
1989-02-01T00:00:00Z